|
| Common target analysis of Ginkgo biloba extract and its active ingredients for co-treatment of cardiovascular and cerebrovascular diseases based on “same treatment for different diseases” theory |
| Hits 2677 Download times 1488 Received:August 26, 2017 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2018.01.19 |
| Key Words
ginkgo biloba extract;cardiovascular disease;cerebral vascular disease;target |
| Author Name | Affiliation | E-mail | | SHI Xinhui | Tianjin University of Traditional Chinese Medicine, Tianjin Key Laboratory of Modern Chinese Medicine, Tianjin 300193, China
Tianjin International Joint Academy of Biomedicine, Tianjin 300457, China | | | LYU Ming | Tianjin University of Traditional Chinese Medicine, Tianjin Key Laboratory of Modern Chinese Medicine, Tianjin 300193, China
Tianjin International Joint Academy of Biomedicine, Tianjin 300457, China | | | ZHU Yan | Tianjin University of Traditional Chinese Medicine, Tianjin Key Laboratory of Modern Chinese Medicine, Tianjin 300193, China
Tianjin International Joint Academy of Biomedicine, Tianjin 300457, China | yanzhu.harvard@gmail.com |
|
| Abstract
|
| Accumulating studies on the pharmacological activities of Ginkgo biloba extract (EGb) and its active ingredients have provided solid evidences on their roles in prevention and treatment of cardiovascular and cerebrovascular diseases. At present, correlation between cardiovascular and cerebrovascular diseases is becoming one of the most active research areas internationally. Literature search and analyses indicated that earlier investigations on EGb and its active ingredients focused on individual diseases with more attention paid to cerebrovascular disease than cardiovascular disease. Using the tool of IPA (ingenuity pathway analysis), we have attempted to reanalyze the literature on Ginkgo biloba extract and its active components with a focus on the interaction between cardiovascular and cerebrovascular disease targets. The results showed that EGb and its active components had different effects on distinct heart and brain targets but their common targets include key molecules for the pathogenesis of atherosclerosis, suggesting that EGb and its active ingredients mayshare different or the same targets to prevent and treat cardiovascular and cerebrovascular diseases. Future in-depth investigation may shed new light on EGb and its active ingredients for the co-treatment of cardiovascular and cerebrovascular diseases based on "same treatment for different diseases" theory |
|
|
|
|
|
|
|
